Literature DB >> 20805035

Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate.

Yun-Zhou Yu1, Wen-Bin Wang, Na Li, Shuang Wang, Wei-Yuan Yu, Zhi-Wei Sun.   

Abstract

DNA vaccines against botulinum neurotoxin (BoNTs) induce protective humoral immune responses in mouse model, but when compared with conventional vaccines such as toxoid and protein vaccines, DNA vaccines often induce lower antibody level and protective efficacy and are still necessary to increase their potency. In this study we evaluated the potency of aluminum phosphate as an adjuvant of DNA vaccines to enhance antibody responses and protective efficacy against botulinum neurotoxin serotypes A and B in Balb/c mice. The administration of these individual and bivalent plasmid DNA replicon vaccines against botulinum neurotoxin serotypes A and B in the presence of aluminum phosphate improved both antibody responses and protective efficacy. Furthermore, formulation of conventional plasmid DNA vaccines encoding the same Hc domains of botulinum neurotoxin serotypes A and B with aluminum phosphate adjuvant increased both antibody responses and protective efficacy. These results indicate aluminum phosphate is an effective adjuvant for these two types of DNA vaccines (i.e., plasmid DNA replicon vaccines and conventional plasmid DNA vaccines), and the vaccine formulation described here may be an excellent candidate for further vaccine development against botulinum neurotoxins.
Copyright © 2010 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805035     DOI: 10.1016/j.biologicals.2010.08.001

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  4 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.

Authors:  Dan-Yang Shi; Bo-Yang Chen; Yun-Yun Mao; Guo Zhou; Jian-Sheng Lu; Yun-Zhou Yu; Xiao-Wei Zhou; Zhi-Wei Sun
Journal:  Hum Vaccin Immunother       Date:  2018-12-04       Impact factor: 3.452

3.  Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.

Authors:  Yao Ma; Huai-Jie An; Xiao-Qi Wei; Qing Xu; Yun-Zhou Yu; Zhi-Wei Sun
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

4.  Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.

Authors:  YunZhou Yu; DanYang Shi; Si Liu; Zheng-Wei Gong; Shuang Wang; ZhiWei Sun
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.